242 related articles for article (PubMed ID: 18519405)
1. Maintenance treatment in multiple myeloma.
Harousseau JL
Ann Oncol; 2008 Jun; 19 Suppl 4():iv54-5. PubMed ID: 18519405
[No Abstract] [Full Text] [Related]
2. New treatments in multiple myeloma: beyond optimal treatment.
Harousseau JL
Ann Oncol; 2008 Jul; 19 Suppl 5():v68-70. PubMed ID: 18611904
[No Abstract] [Full Text] [Related]
3. Diagnosis and the current trends in multiple myeloma therapy.
DmoszyĆska A
Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
[TBL] [Abstract][Full Text] [Related]
4. [Recent progress in diagnosis of and therapy for multiple myeloma].
Okamoto S
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1922-31. PubMed ID: 17037337
[No Abstract] [Full Text] [Related]
5. [A cure for multiple myeloma?].
Harousseau JL
Presse Med; 2006 Sep; 35(9 Pt 2):1288-90. PubMed ID: 16969322
[No Abstract] [Full Text] [Related]
6. The emerging role of novel therapies for the treatment of relapsed myeloma.
Richardson PG; Hideshima T; Mitsiades C; Anderson KC
J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma.
Kyle RA; Rajkumar SV
N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
[No Abstract] [Full Text] [Related]
8. Frontline treatment of multiple myeloma.
Fonseca R
Hematology; 2012 Apr; 17 Suppl 1():S101-4. PubMed ID: 22507793
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and therapy of multiple myeloma.
Palumbo A; Cerrato C
Korean J Intern Med; 2013 May; 28(3):263-73. PubMed ID: 23682217
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide for bortezomib-resistant multiple myeloma.
Briani C; Berno T; Campagnolo M; Zambello R
Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906
[No Abstract] [Full Text] [Related]
11. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
13. Novel agents for multiple myeloma treatment.
Ribatti D; Vacca A
Curr Pharm Biotechnol; 2006 Dec; 7(6):395. PubMed ID: 17168654
[No Abstract] [Full Text] [Related]
14. Multiple myeloma.
Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide efficacy in bortezomib-resistant myeloma.
Gozzetti A; Crupi R; Defina M; Bocchia M
Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907
[No Abstract] [Full Text] [Related]
16. Treatment of newly diagnosed multiple myeloma.
Palumbo A; Magarotto V; Larocca A; Bringhen S; Falco P; Di Raimondo F; Baldini L; Boccadoro M
Curr Hematol Malig Rep; 2008 Apr; 3(2):107-14. PubMed ID: 20425454
[TBL] [Abstract][Full Text] [Related]
17. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Kumar S; Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Lentzsch S; Munshi N; Niesvizky R; San Miguel J; Ludwig H; Bergsagel L; Blade J; Lonial S; Anderson KC; Tosi P; Sonneveld P; Sezer O; Vesole D; Cavo M; Einsele H; Richardson PG; Durie BG; Rajkumar SV;
Blood; 2009 Aug; 114(9):1729-35. PubMed ID: 19561323
[TBL] [Abstract][Full Text] [Related]
18. NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
Burke MJ; George E; Adler AI
Lancet Oncol; 2015 May; 16(5):492-3. PubMed ID: 25818587
[No Abstract] [Full Text] [Related]
19. Novel agents in the frontline management of multiple myeloma.
Loong HH
Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
[TBL] [Abstract][Full Text] [Related]
20. Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Yaqub S; Ballester G; Ballester O
Cancer Invest; 2013 Oct; 31(8):529-37. PubMed ID: 24083815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]